Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
71High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07350928CT.gov Observation of the Effect of Preoperative Use of Dexmedetomidine Hydrochloride Nasal Spray on Optimizing Awake Sedation During Breast-Conserving Surgery for Breast Cancer and Postoperative Awake Status | — | Recruiting | — | — | — |
NCT06252662CT.gov Liposomal Bupivacaine Vs Bupivacaine with Dexmedetomidine in Erector Spinae Plane Blocks for Mastectomies | — | Recruiting | — | — | — |
NCT06300099CT.gov Dexamethasone Versus Dexmedetomidine as Adjuncts to Serratus Anterior Plane Block | — | Unknown | — | — | — |
NCT07180810CT.gov Effect of Dexmedetomidine Infusion on Post Anesthesia Discharge Time | — | Completed | — | — | — |
NCT05732064CT.gov Dexmedetomidine-esketamine Combined Nasal Administration and Perioperative Sleep Quality | — | Completed | — | — | — |
NCT05727098CT.gov Dexmedetomedine and Ketamine in Erector Spinae Block for Postoperative Analgesia Following Mastectomy. | — | Completed | — | — | — |
NCT05439005CT.gov Opioid Free Versus Opioid Based Anaesthesia for Free Flap Reconstruction Surgery of the Breast: A Phase III Multicentric Randomized Controlled Study. | — | Recruiting | — | — | — |
NCT07081581CT.gov Analgesic Effect of Serratus Plane Block With Adjuvant Agents in Breast Cancer Surgery | — | Completed | — | — | — |
NCT04029467CT.gov Effect of Dexmedetomidine on the Duration of Pain Control in ESP Block for Breast Surgery | — | Unknown | — | — | — |
NCT04238377CT.gov Post Mastectomy Pain Syndrome After Preoperative Stellate Ganglion Block for Breast Cancer Surgeries | — | Unknown | — | — | — |
Show 8 more trialsShow fewer
NCT03108937CT.gov Effects of Dexmedetomidine on Breast Cancer Cell Function in Vitro | — | Completed | — | — | — |
NCT03063073CT.gov Efficacy and Safety of Dexmedetomidine Added to Modified Pectoral's Block | — | Completed | — | — | — |
NCT03046238CT.gov Efficacy and Safety of Dexmedetomidine Added to Modified Pectoral's Block in Breast Cancer Patients | — | Unknown | — | — | — |
NCT03109990CT.gov A Pilot Study to Evaluate the Impact of Dexmedetomidine on Breast Cancer Recurrence After Surgery | — | Completed | — | — | — |
NCT02675049CT.gov Efficacy and Optimal Dose Selection of Intranasal Dexmedetomidine During Breast Lumpectomy Under Local Anaesthesia | — | Completed | — | — | — |
NCT03456661CT.gov Comparison Between Levobupivacaine and Levobupivacaine With Dexmedetomidine in Ultrasound Guided Pectoral Nerve Block | — | Terminated | — | — | — |
NCT01692210CT.gov The Effect of Dexmedetomidine of the Immune System | — | Completed | — | — | — |
NCT01548209CT.gov Effects of a Dexmedetomidine on Quality of Recovery 40 and Postoperative Nausea and Vomiting in Breast Cancer Surgery | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Breast Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Dexmedetomidine (this asset) | Tianjin Medical University Cancer Institute and Hospital | Approved | BB · 66 |
| Darolutamide | Vandana Abramson | P2 | BBB |
| Pertuzumab | SWOG Cancer Research Network | P4 | BB |
| Palbociclib | Hoffmann-La Roche | P4 | BB |
| Trastuzumab Duocarmazine | Byondis B.V. | P3 | BB |
| Goserelin | TerSera Therapeutics LLC | P4 | BB |
| Ribociclib | National Cancer Institute (NCI) | P4 | BB |
| Oxaliplatin | Beijing Biostar Pharmaceuticals Co., Ltd. | P4 | BB |
| Eribulin Monomethanesulfonate | Henan Cancer Hospital | P4 | BB |
+42 more in the Breast Cancer cohort
Other indications for Dexmedetomidine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Schizophreniform Disorder | — | P4 | A · 80 |
| Schizoaffective Disorder | — | P4 | BBB · 77 |
| Neuralgia | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Dexmedetomidine in Breast Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/dexmedetomidine-breast-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →